Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 722

1.

Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs.

Osborn MJ, Newby GA, McElroy AN, Knipping F, Nielsen SC, Riddle MJ, Xia L, Chen W, Eide CR, Webber BR, Wandall HH, Dabelsteen S, Blazar BR, Liu DR, Tolar J.

J Invest Dermatol. 2019 Aug 19. pii: S0022-202X(19)32698-3. doi: 10.1016/j.jid.2019.07.701. [Epub ahead of print]

PMID:
31437443
2.

Early E. casseliflavus gut colonization and outcomes of allogeneic hematopoietic cell transplantation.

Rashidi A, Ebadi M, Shields-Cutler RR, Kruziki K, Manias DA, Barnes AMT, DeFor TE, Ferrieri P, Young JH, Knights D, Blazar BR, Weisdorf DJ, Dunny GM.

PLoS One. 2019 Aug 8;14(8):e0220850. doi: 10.1371/journal.pone.0220850. eCollection 2019.

3.

Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease.

Holtan SG, Shabaneh A, Betts BC, Rashidi A, MacMillan ML, Ustun C, Amin K, Vaughn BP, Howard J, Khoruts A, Arora M, DeFor TE, Johnson D, Blazar BR, Weisdorf DJ, Wang J.

JCI Insight. 2019 Aug 8;5. pii: 129762. doi: 10.1172/jci.insight.129762.

4.

Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.

Nature. 2019 Aug;572(7770):E19. doi: 10.1038/s41586-019-1475-x.

PMID:
31367045
5.

Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease.

Rashidi A, DeFor TE, Holtan SG, Blazar BR, Weisdorf DJ, MacMillan ML.

Biol Blood Marrow Transplant. 2019 Jul 17. pii: S1083-8791(19)30449-5. doi: 10.1016/j.bbmt.2019.07.017. [Epub ahead of print]

PMID:
31325587
6.

Validation of Minnesota acute graft-versus-host disease Risk Score.

MacMillan ML, DeFor TE, Holtan SG, Rashidi A, Blazar BR, Weisdorf DJ.

Haematologica. 2019 Jul 18. pii: haematol.2019.220970. doi: 10.3324/haematol.2019.220970. [Epub ahead of print]

7.

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C.

Nature. 2019 Aug;572(7768):254-259. doi: 10.1038/s41586-019-1410-1. Epub 2019 Jul 17. Erratum in: Nature. 2019 Aug 1;:.

PMID:
31316209
8.

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.

Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger JM, Robertson P, Grzywacz B, Conlon KC, Waldmann TA, McKenna DH, Blazar BR, Weisdorf DJ, Miller JS.

Blood Adv. 2019 Jul 9;3(13):1970-1980. doi: 10.1182/bloodadvances.2018028332.

9.

Activated Protein C Ameliorates Chronic Graft-Versus-Host Disease by PAR1-dependent Biased Cell Signaling on T-cells.

Sinha RK, Flynn R, Zaiken M, Paz K, Gavin AL, Nemazee D, Fernández JA, Xu X, Griffin JH, Blazar BR.

Blood. 2019 Jun 26. pii: blood.2019001259. doi: 10.1182/blood.2019001259. [Epub ahead of print]

PMID:
31243040
10.

Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming.

Merino A, Zhang B, Dougherty P, Luo X, Wang J, Blazar BR, Miller JS, Cichocki F.

J Clin Invest. 2019 Jun 18;130. pii: 125916. doi: 10.1172/JCI125916.

11.

Early Notch Signals Induce a Pathogenic Molecular Signature during Priming of Alloantigen-Specific Conventional CD4+ T Cells in Graft-versus-Host Disease.

Chung J, Radojcic V, Perkey E, Parnell TJ, Niknafs Y, Jin X, Friedman A, Labrecque N, Blazar BR, Brennan TV, Siebel CW, Maillard I.

J Immunol. 2019 Jul 15;203(2):557-568. doi: 10.4049/jimmunol.1900192. Epub 2019 Jun 10.

PMID:
31182480
12.

Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets.

Tanimine N, Germana SK, Fan M, Hippen K, Blazar BR, Markmann JF, Turka LA, Priyadharshini B.

PLoS One. 2019 Jun 6;14(6):e0217761. doi: 10.1371/journal.pone.0217761. eCollection 2019.

13.

Polyamines and eIF5A Hypusination Modulate Mitochondrial Respiration and Macrophage Activation.

Puleston DJ, Buck MD, Klein Geltink RI, Kyle RL, Caputa G, O'Sullivan D, Cameron AM, Castoldi A, Musa Y, Kabat AM, Zhang Y, Flachsmann LJ, Field CS, Patterson AE, Scherer S, Alfei F, Baixauli F, Austin SK, Kelly B, Matsushita M, Curtis JD, Grzes KM, Villa M, Corrado M, Sanin DE, Qiu J, Pällman N, Paz K, Maccari ME, Blazar BR, Mittler G, Buescher JM, Zehn D, Rospert S, Pearce EJ, Balabanov S, Pearce EL.

Cell Metab. 2019 Aug 6;30(2):352-363.e8. doi: 10.1016/j.cmet.2019.05.003. Epub 2019 May 23.

14.

Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.

Holtan SG, Zhang L, DeFor TE, Bejanyan N, Arora M, Rashidi A, Lazaryan A, Kotiso F, Blazar BR, Wagner JE, Brunstein CG, MacMillan ML, Weisdorf DJ.

Biol Blood Marrow Transplant. 2019 May 22. pii: S1083-8791(19)30326-X. doi: 10.1016/j.bbmt.2019.05.015. [Epub ahead of print]

PMID:
31128328
15.

Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization.

Leung WH, Gay J, Martin U, Garrett TE, Horton HM, Certo MT, Blazar BR, Morgan RA, Gregory PD, Jarjour J, Astrakhan A.

JCI Insight. 2019 Apr 30;5. pii: 124430. doi: 10.1172/jci.insight.124430.

16.

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.

Belizaire R, Kim HT, Poryanda SJ, Mirkovic NV, Hipolito E, Savage WJ, Reynolds CG, Fields MJ, Whangbo J, Kubo T, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Blazar BR, Antin JH, Ritz J, Soiffer RJ, Koreth J.

Blood Adv. 2019 Apr 9;3(7):969-979. doi: 10.1182/bloodadvances.2018029124.

17.

Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease.

Thangavelu G, Blazar BR.

Front Immunol. 2019 Mar 6;10:309. doi: 10.3389/fimmu.2019.00309. eCollection 2019. Review.

18.

TRAF6 directs FOXP3 localization and facilitates regulatory T-cell function through K63-linked ubiquitination.

Ni X, Kou W, Gu J, Wei P, Wu X, Peng H, Tao J, Yan W, Yang X, Lebid A, Park BV, Chen Z, Tian Y, Fu J, Newman S, Wang X, Shen H, Li B, Blazar BR, Wang X, Barbi J, Pan F, Lu L.

EMBO J. 2019 May 2;38(9). pii: e99766. doi: 10.15252/embj.201899766. Epub 2019 Mar 18.

19.

Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality.

Thangavelu G, Lee YC, Loschi M, Schaechter KM, Feser CJ, Koehn BH, Nowak EC, Zeiser R, Serody JS, Murphy WJ, Munn DH, Chambon P, Noelle RJ, Blazar BR.

J Immunol. 2019 May 1;202(9):2795-2805. doi: 10.4049/jimmunol.1800899. Epub 2019 Mar 18.

PMID:
30885956
20.

CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration.

Xiong Y, Piao W, Brinkman CC, Li L, Kulinski JM, Olivera A, Cartier A, Hla T, Hippen KL, Blazar BR, Schwab SR, Bromberg JS.

Sci Immunol. 2019 Mar 15;4(33). pii: eaav1263. doi: 10.1126/sciimmunol.aav1263.

PMID:
30877143
21.

Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.

Boroughs AC, Larson RC, Choi BD, Bouffard AA, Riley LS, Schiferle E, Kulkarni AS, Cetrulo CL, Ting D, Blazar BR, Demehri S, Maus MV.

JCI Insight. 2019 Mar 14;5. pii: 126194. doi: 10.1172/jci.insight.126194.

22.

Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth.

Phan T, Nguyen VH, D'Alincourt MS, Manuel ER, Kaltcheva T, Tsai W, Blazar BR, Diamond DJ, Melstrom LG.

Cancer Gene Ther. 2019 Mar 1. doi: 10.1038/s41417-019-0089-7. [Epub ahead of print]

PMID:
30824815
23.

Targeting PI3Kδ function for amelioration of murine chronic graft-versus-host disease.

Paz K, Flynn R, Du J, Tannheimer S, Johnson AJ, Dong S, Stark AK, Okkenhaug K, Panoskaltsis-Mortari A, Sage PT, Sharpe AH, Luznik L, Ritz J, Soiffer RJ, Cutler CS, Koreth J, Antin JH, Miklos DB, MacDonald KP, Hill GR, Maillard I, Serody JS, Murphy WJ, Munn DH, Feser C, Zaiken M, Vanhaesebroeck B, Turka LA, Byrd JC, Blazar BR.

Am J Transplant. 2019 Jun;19(6):1820-1830. doi: 10.1111/ajt.15305. Epub 2019 Mar 19.

PMID:
30748099
24.

Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy.

Rosato PC, Wijeyesinghe S, Stolley JM, Nelson CE, Davis RL, Manlove LS, Pennell CA, Blazar BR, Chen CC, Geller MA, Vezys V, Masopust D.

Nat Commun. 2019 Feb 4;10(1):567. doi: 10.1038/s41467-019-08534-1.

25.

FoxP3 and Ezh2 regulate Tfr cell suppressive function and transcriptional program.

Hou S, Clement RL, Diallo A, Blazar BR, Rudensky AY, Sharpe AH, Sage PT.

J Exp Med. 2019 Mar 4;216(3):605-620. doi: 10.1084/jem.20181134. Epub 2019 Jan 31.

PMID:
30705058
26.

Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.

Yang J, Ramadan A, Reichenbach DK, Loschi M, Zhang J, Griesenauer B, Liu H, Hippen KL, Blazar BR, Paczesny S.

JCI Insight. 2019 Mar 7;4(5). pii: 122014. doi: 10.1172/jci.insight.122014. eCollection 2019 Mar 7.

27.

Adaptive NK cell reconstitution is associated with better clinical outcomes.

Cichocki F, Taras E, Chiuppesi F, Wagner JE, Blazar BR, Brunstein C, Luo X, Diamond DJ, Cooley S, Weisdorf DJ, Miller JS.

JCI Insight. 2019 Jan 24;4(2). pii: 125553. doi: 10.1172/jci.insight.125553. [Epub ahead of print]

28.

The lineage stability and suppressive program of regulatory T cells require protein O-GlcNAcylation.

Liu B, Salgado OC, Singh S, Hippen KL, Maynard JC, Burlingame AL, Ball LE, Blazar BR, Farrar MA, Hogquist KA, Ruan HB.

Nat Commun. 2019 Jan 21;10(1):354. doi: 10.1038/s41467-019-08300-3.

29.

Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes.

Turcotte LM, Cao Q, Cooley SA, Curtsinger J, Holtan SG, Luo X, Yingst A, Weisdorf DJ, Blazar BR, Miller JS, Wagner JE, Verneris MR.

Biol Blood Marrow Transplant. 2019 May;25(5):883-890. doi: 10.1016/j.bbmt.2019.01.003. Epub 2019 Jan 6.

PMID:
30625388
30.

Reduction in murine acute GVHD severity by human gingival tissue-derived mesenchymal stem cells via the CD39 pathways.

Ni X, Xia Y, Zhou S, Peng H, Wu X, Lu H, Wang H, Liu R, Blazar BR, Gu J, Lu L.

Cell Death Dis. 2019 Jan 8;10(1):13. doi: 10.1038/s41419-018-1273-7.

31.

Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.

Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CH, Frieling J, Lynch CC, List A, Rodriguez PC, Blazar BR, Conejo-Garcia JR, Del Valle JR, Hu CC, Anasetti C.

Front Immunol. 2018 Dec 6;9:2887. doi: 10.3389/fimmu.2018.02887. eCollection 2018.

32.

C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans.

Verghese DA, Chun N, Paz K, Fribourg M, Woodruff TM, Flynn R, Hu Y, Xiong H, Zhang W, Yi Z, Du J, Blazar BR, Heeger PS.

JCI Insight. 2018 Dec 20;3(24). pii: 124646. doi: 10.1172/jci.insight.124646.

33.

Induction of immunosuppressive functions and NF-κB by FLIP in monocytes.

Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Bicciato S, Blazar BR, Sahin U, Murray PJ, Bronte V.

Nat Commun. 2018 Dec 5;9(1):5193. doi: 10.1038/s41467-018-07654-4.

34.

Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease.

Rashidi A, Shanley R, Holtan SG, MacMillan ML, Blazar BR, Khoruts A, Weisdorf DJ.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2190-2196. doi: 10.1016/j.bbmt.2018.06.036. Epub 2018 Jul 7.

PMID:
30454871
35.

Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid.

Amin K, Yaqoob U, Schultz B, Vaughn BP, Khoruts A, Howard JR, DeFor TE, Forster C, Meyer C, Gandhi I, Weisdorf DJ, Rashidi A, MacMillan ML, Blazar BR, Panoskaltsis-Mortari A, Holtan SG.

Mod Pathol. 2019 Apr;32(4):560-567. doi: 10.1038/s41379-018-0170-z. Epub 2018 Nov 13.

PMID:
30425334
36.

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.

Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM.

Nat Med. 2019 Jan;25(1):141-151. doi: 10.1038/s41591-018-0221-5. Epub 2018 Nov 12.

37.

Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism.

Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, Newcomb DC, Wells AD, Restifo NP, Rathmell WK, Locasale JW, Davila ML, Blazar BR, Rathmell JC.

Cell. 2018 Dec 13;175(7):1780-1795.e19. doi: 10.1016/j.cell.2018.10.001. Epub 2018 Nov 1.

PMID:
30392958
38.

Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.

Knaus HA, Berglund S, Hackl H, Blackford AL, Zeidner JF, Montiel-Esparza R, Mukhopadhyay R, Vanura K, Blazar BR, Karp JE, Luznik L, Gojo I.

JCI Insight. 2018 Nov 2;3(21). pii: 120974. doi: 10.1172/jci.insight.120974.

39.

Thymic Epithelial Cell Support of Thymopoiesis Does Not Require Klotho.

Xing Y, Smith MJ, Goetz CA, McElmurry RT, Parker SL, Min D, Hollander GA, Weinberg KI, Tolar J, Stefanski HE, Blazar BR.

J Immunol. 2018 Dec 1;201(11):3320-3328. doi: 10.4049/jimmunol.1800670. Epub 2018 Oct 29.

PMID:
30373854
40.

Helminth-Induced Production of TGF-β and Suppression of Graft-versus-Host Disease Is Dependent on IL-4 Production by Host Cells.

Li Y, Guan X, Liu W, Chen HL, Truscott J, Beyatli S, Metwali A, Weiner GJ, Zavazava N, Blumberg RS, Urban JF Jr, Blazar BR, Elliott DE, Ince MN.

J Immunol. 2018 Nov 15;201(10):2910-2922. doi: 10.4049/jimmunol.1700638. Epub 2018 Oct 5.

PMID:
30291167
41.

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.

Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Cutler CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Bradner JE, Melnick AM, Blazar BR.

Blood. 2019 Jan 3;133(1):94-99. doi: 10.1182/blood-2018-03-839993. Epub 2018 Oct 2.

PMID:
30279226
42.

STAT6 and Furin Are Successive Triggers for the Production of TGF-β by T Cells.

Li Y, Liu W, Guan X, Truscott J, Creemers JW, Chen HL, Pesu M, El Abiad RG, Karacay B, Urban JF Jr, Elliott DE, Kaplan MH, Blazar BR, Ince MN.

J Immunol. 2018 Nov 1;201(9):2612-2623. doi: 10.4049/jimmunol.1700808. Epub 2018 Sep 28.

PMID:
30266770
43.

Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD.

Kolupaev OV, Dant TA, Bommiasamy H, Bruce DW, Fowler KA, Tilley SL, McKinnon KP, Sarantopoulos S, Blazar BR, Coghill JM, Serody JS.

Blood Adv. 2018 Sep 25;2(18):2307-2319. doi: 10.1182/bloodadvances.2017014977. Epub 2018 Sep 18.

44.

Cutting Edge: TGF-β and Phosphatidylinositol 3-Kinase Signals Modulate Distinct Metabolism of Regulatory T Cell Subsets.

Priyadharshini B, Loschi M, Newton RH, Zhang JW, Finn KK, Gerriets VA, Huynh A, Rathmell JC, Blazar BR, Turka LA.

J Immunol. 2018 Oct 15;201(8):2215-2219. doi: 10.4049/jimmunol.1800311. Epub 2018 Sep 12.

PMID:
30209190
45.

Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice.

Radojcic V, Paz K, Chung J, Du J, Perkey ET, Flynn R, Ivcevic S, Zaiken M, Friedman A, Yan M, Pletneva MA, Sarantopoulos S, Siebel CW, Blazar BR, Maillard I.

Blood. 2018 Nov 15;132(20):2188-2200. doi: 10.1182/blood-2018-03-841155. Epub 2018 Sep 4.

PMID:
30181175
46.

Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD.

Rashidi A, Shanley R, Anasetti C, Waller EK, Scott BL, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2019 Mar;54(3):490-493. doi: 10.1038/s41409-018-0331-1. Epub 2018 Aug 31. No abstract available.

PMID:
30171221
47.

How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.

Jaglowski SM, Blazar BR.

Blood Adv. 2018 Aug 14;2(15):2012-2019. doi: 10.1182/bloodadvances.2018013060. Review.

48.

The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease.

McDonald-Hyman C, Muller JT, Loschi M, Thangavelu G, Saha A, Kumari S, Reichenbach DK, Smith MJ, Zhang G, Koehn BH, Lin J, Mitchell JS, Fife BT, Panoskaltsis-Mortari A, Feser CJ, Kirchmeier AK, Osborn MJ, Hippen KL, Kelekar A, Serody JS, Turka LA, Munn DH, Chi H, Neubert TA, Dustin ML, Blazar BR.

J Clin Invest. 2018 Oct 1;128(10):4604-4621. doi: 10.1172/JCI95713. Epub 2018 Aug 14.

49.

CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates.

Watkins BK, Tkachev V, Furlan SN, Hunt DJ, Betz K, Yu A, Brown M, Poirier N, Zheng HB, Taraseviciute A, Colonna L, Mary C, Blancho G, Soulillou JP, Panoskaltsis-Mortari A, Sharma P, Garcia A, Strobert E, Hamby K, Garrett A, Deane T, Blazar BR, Vanhove B, Kean LS.

J Clin Invest. 2018 Aug 31;128(9):3991-4007. doi: 10.1172/JCI98793. Epub 2018 Aug 13.

50.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML.

Blood Adv. 2018 Aug 14;2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343.

Supplemental Content

Loading ...
Support Center